Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
Sarah B. Goldberg
No relevant relationships to disclose
Geoffrey R. Oxnard
Consultant or Advisory Role - Genentech
Subba Digumarthy
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
David Michael Jackman
Consultant or Advisory Role - Foundation Medicine; Genentech
Inga Tolin Lennes
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)